associated with drug action and disease (www.metabolon.com);

• Molecular Biometrics, Inc., a diagnostics company developing analytical methodologies and products for diagnosis and monitoring applications with an initial focus in IVF (in vitro fertilization) (www.molecularbiometrics.com); and
• Zetek, LLC, a diagnostics company in the field of fertility and conception management in humans and livestock (the latter through Animark, Inc.) (www.zetek.net). 

Mr. Erickson has also served as an independent director on several public company boards, including Barrier Therapeutics, Inc. {NASDAQ:BTRX}, a pharmaceutical company in the field of dermatology, acquired by Stiefel Laboratories, Inc. in 2008. His board committee experience includes audit (chairmanships and designation as a “financial expert” under the Sarbanes-Oxley Act of 2002), compensation, nominating and governance and ad hoc committees overseeing special transactions such as M&A. Since 2006 he has served as an advisor to Safeguard Scientifics, Inc., a publicly traded holding company that builds value in growth-stage technology and life sciences businesses by providing capital, as well as a range of strategic, operational and management resources.

Next >

Edward L. Erickson is a consultant to entrepreneurial companies and venture capital firms. He has extensive experience in the life science industries having served as president, CEO or a director of more than a dozen such companies, four of which successfully completed IPOs during his tenure. He has raised a total of approximately $500,000,000 in equity and debt capital in the private and public capital markets. He also has considerable experience gained earlier in his career in defense, energy, natural resources and information technology.

Mr. Erickson has substantial board experience as a director, including chairman roles, of both private and public companies and currently serves on the boards of:

t